News about Global Pharma

Ionis Receives FDA Approval of New Drug Application for Donidalorsen

Donidalorsen is designed to reduce the production of prekallikrein (PKK), interrupting the pathway that leads to HAE attacks.

Global Pharma | 06/11/2024 | By Aishwarya |  993

Scorpius Teams Up with Celltheon to Offer Affordable Biotherapeutics

This collaboration enables clients to integrate with Scorpius’ program management team and quality system while preparing to transfer a research cell bank (RCB) to the company’s facilities in San Antonio, TX, for further biomanufacturing work.

Global Pharma | 05/11/2024 | By Aishwarya |  469

CureVac Welcomes Axel Sven Malkomes as New Chief Financial Officer

Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries.

Global Pharma | 05/11/2024 | By Aishwarya |  529

Gland Pharma Reports Revenue of INR 14,058 Million in Q2FY25

Gland Pharma has reported a consolidated revenue of INR 14,058 million for Q2 FY25, marking a 2 percent increase compared to INR 13,734 million in Q2 FY24.

Global Pharma | 05/11/2024 | By Aishwarya |  1321

Syntegon and Abzil Close Acquisition of Telstar

The Telstar workforce will now join the Syntegon team in the Pharma Liquid Business Unit.

Global Pharma | 04/11/2024 | By Aishwarya |  1392

Lipocine Signs License Deal with SPC Korea to Commercialize TLANDO in South Korea

Under the terms of the distribution and license agreement, Lipocine will receive an upfront payment and is also eligible to receive certain regulatory and sales milestone payments, including payment upon regulatory approval of TLANDO in South Korea.

Global Pharma | 04/11/2024 | By Aishwarya |  481

Acumen Pharma Presents New Data on pTau217 Assay at Annual CTAD Conference

The study found that this enrichment screening approach is resulting in a higher proportion of participants who meet the amyloid PET or CSF-based inclusion criteria compared to Acumen’s Phase 1 INTERCEPT-AD trial, which did not use this approach.

Global Pharma | 01/11/2024 | By Aishwarya |  615

Emcure Launches New Entity Emcutix Biopharmaceuticals for Dermatology Sector

As a part of this strategic initiative, Emcure's existing dermatology business will also operate under Emcutix.

Global Pharma | 29/10/2024 | By Aishwarya |  1156

Indegene Achieves Revenue of INR 6,868 Million in Q2FY25

In the second quarter of the financial year 2025, Indegene achieved revenue from operations totaling INR 6,868 million, marking an 8.0 percent Year-over-Year (YoY) growth compared to the same period in the previous year.

Global Pharma | 29/10/2024 | By Aishwarya |  951

LakeShore Biopharma Gets Phase III Clinical Trial Approval for YSJA Rabies Vaccine

The Trial, which is expected to begin in December 2024, will evaluate the immunogenicity and safety of the YSJA rabies vaccine across two distinct four-dose immunization schedules to determine their immunogenicity and safety compared to the existing Essen regimen (1-1-1-1-1).

Global Pharma | 28/10/2024 | By Aishwarya |  746